Literature DB >> 21722583

Reduction of postprandial glycemic excursions in patients with type 1 diabetes: a novel human insulin formulation versus a rapid-acting insulin analog and regular human insulin.

Lutz Heinemann1, Marcus Hompesch, Frank Flacke, Patrick Simms, Rody Pohl, Kerstin Albus, Andreas Pfützner, Solomon Steiner.   

Abstract

BACKGROUND: Evaluation of postprandial glycemic excursions in patients with type 1 diabetes with three prandial insulins: VIAject™ (Linjeta™), an ultra-fast insulin (UFI); insulin lispro (LIS); and regular human insulin (RHI).
METHODS: After stabilization of preprandial glycemia, 18 patients received a subcutaneous injection with an individualized insulin dose prior to a meal.
RESULTS: Injection of UFI resulted in a more rapid insulin absorption than with either LIS or RHI (time to half-maximal insulin levels: 13.1 ± 5.2 vs 25.4 ± 7.6 and 38.4 ± 19.5 min; p = .001 vs LIS and p < .001 vs RHI, LIS vs. RHI p < .001). Maximal postprandial glycemia was lower with UFI (0-180 min; 157 ± 30 mg/dl; p = .002 vs RHI) and LIS (170 ± 42 mg/dl; p = .668 vs RHI) than after RHI (191 ± 46 mg/dl; RHI vs LIS p = .008). The difference between maximum and minimum glycemia was smaller with UFI (70 ± 17 mg/dl) than with either RHI (91 ± 33 mg/dl; p = .007 vs UFI) or LIS (89 ± 18 mg/dl; p = .011 vs UFI). Also, the area under the blood glucose profile was lower with UFI than with RHI (0-180 min; 21.8 ± 5.8 vs 28.4 ± 7.6 g·min/dl; p < .001).
CONCLUSIONS: The rapid absorption of UFI results in a reduction of postprandial glycemic excursions.
© 2011 Diabetes Technology Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21722583      PMCID: PMC3192634          DOI: 10.1177/193229681100500322

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  12 in total

1.  Injection-meal interval: recommendations of diabetologists and how patients handle it.

Authors:  H Overmann; L Heinemann
Journal:  Diabetes Res Clin Pract       Date:  1999-02       Impact factor: 5.602

2.  Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients.

Authors:  D Bruttomesso; A Pianta; A Mari; A Valerio; M C Marescotti; A Avogaro; A Tiengo; S Del Prato
Journal:  Diabetes       Date:  1999-01       Impact factor: 9.461

3.  Microneedle-based intradermal versus subcutaneous administration of regular human insulin or insulin lispro: pharmacokinetics and postprandial glycemic excursions in patients with type 1 diabetes.

Authors:  Ronald J Pettis; Laurence Hirsch; Christoph Kapitza; Leszek Nosek; Ulrike Hövelmann; Heinz-Joerg Kurth; Diane E Sutter; Noel G Harvey; Lutz Heinemann
Journal:  Diabetes Technol Ther       Date:  2011-02-28       Impact factor: 6.118

4.  Timing of meal insulin boluses to achieve optimal postprandial glycemic control in patients with type 1 diabetes.

Authors:  Erin Cobry; Kim McFann; Laurel Messer; Victoria Gage; Brandon VanderWel; Lauren Horton; H Peter Chase
Journal:  Diabetes Technol Ther       Date:  2010-03       Impact factor: 6.118

5.  Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients: using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin.

Authors:  L Heinemann; T Heise; L C Wahl; M E Trautmann; J Ampudia; A A Starke; M Berger
Journal:  Diabet Med       Date:  1996-07       Impact factor: 4.359

6.  Premeal injection of rapid-acting insulin reduces postprandial glycemic excursions in type 1 diabetes.

Authors:  Yoeri M Luijf; Arianne C van Bon; Joost B Hoekstra; J Hans Devries
Journal:  Diabetes Care       Date:  2010-08-06       Impact factor: 19.112

7.  Intra-individual variability of the metabolic effect of a novel rapid-acting insulin (VIAject) in comparison to regular human insulin.

Authors:  Marcus Hompesch; Laura McManus; Roderike Pohl; Patrick Simms; Andreas Pfützner; Elena Bülow; Frank Flacke; Lutz Heinemann; Solomon S Steiner
Journal:  J Diabetes Sci Technol       Date:  2008-07

8.  Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion.

Authors:  Itamar Raz; Ram Weiss; Yevgeny Yegorchikov; Gabriel Bitton; Ron Nagar; Benny Pesach
Journal:  Clin Ther       Date:  2009-05       Impact factor: 3.393

9.  Accelerated pharmacokinetics and glucodynamics of prandial insulins injected with recombinant human hyaluronidase.

Authors:  Daniel E Vaughn; Richard C Yocum; Douglas B Muchmore; Barry J Sugarman; Andrew M Vick; Igor P Bilinsky; Gregory I Frost
Journal:  Diabetes Technol Ther       Date:  2009-06       Impact factor: 6.118

10.  A novel insulin formulation with a more rapid onset of action.

Authors:  S Steiner; M Hompesch; R Pohl; P Simms; F Flacke; T Mohr; A Pfützner; L Heinemann
Journal:  Diabetologia       Date:  2008-07-19       Impact factor: 10.122

View more
  15 in total

1.  Subcutaneous injection versus subcutaneous infusion of insulin: are the rates of absorption truly the same?

Authors:  Lutz Heinemann; Solomon Steiner
Journal:  J Diabetes Sci Technol       Date:  2011-09-01

2.  Faster in and faster out: accelerating insulin absorption and action by insulin infusion site warming.

Authors:  Eda Cengiz; Stuart A Weinzimer; Jennifer L Sherr; Eileen M Tichy; Lori Carria; Darryll Cappiello; Amy Steffen; William V Tamborlane
Journal:  Diabetes Technol Ther       Date:  2013-12-24       Impact factor: 6.118

3.  Accelerating and improving the consistency of rapid-acting analog insulin absorption and action for both subcutaneous injection and continuous subcutaneous infusion using recombinant human hyaluronidase.

Authors:  Douglas B Muchmore; Daniel E Vaughn
Journal:  J Diabetes Sci Technol       Date:  2012-07-01

4.  Improved Postprandial Glucose Control Using the InsuPad Device in Insulin-Treated Type 2 Diabetes: Injection Site Warming to Improve Glycemic Control.

Authors:  Itamar Raz; Gabriel Bitton; Dmitry Feldman; Tal Alon; Andreas Pfutzner; William V Tamborlane
Journal:  J Diabetes Sci Technol       Date:  2015-04-16

5.  Insulin therapies: Current and future trends at dawn.

Authors:  Subhashini Yaturu
Journal:  World J Diabetes       Date:  2013-02-15

6.  Short acting insulin analogues in intensive care unit patients.

Authors:  Federico Bilotta; Carolina Guerra; Rafael Badenes; Simona Lolli; Giovanni Rosa
Journal:  World J Diabetes       Date:  2014-06-15

7.  Ultra-rapid absorption of recombinant human insulin induced by zinc chelation and surface charge masking.

Authors:  Roderike Pohl; Robert Hauser; Ming Li; Errol De Souza; Robert Feldstein; Richard Seibert; Koray Ozhan; Nandini Kashyap; Solomon Steiner
Journal:  J Diabetes Sci Technol       Date:  2012-07-01

Review 8.  A review of a family of ultra-rapid-acting insulins: formulation development.

Authors:  Alan Krasner; Roderike Pohl; Patrick Simms; Philip Pichotta; Robert Hauser; Errol De Souza
Journal:  J Diabetes Sci Technol       Date:  2012-07-01

Review 9.  Ultrafast-acting insulins: state of the art.

Authors:  Lutz Heinemann; Douglas B Muchmore
Journal:  J Diabetes Sci Technol       Date:  2012-07-01

10.  Postprandial plasma glucose response and gastrointestinal symptom severity in patients with diabetic gastroparesis.

Authors:  Eva A Olausson; Håkan Grundin; Mats Isaksson; Christina Brock; Asbjørn M Drewes; Stig Attvall; Magnus Simrén
Journal:  J Diabetes Sci Technol       Date:  2014-05-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.